Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 10, 2026, 11:51 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1129–1152 of 3,528 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: biospecimen Collection Clear all

Conditions: Chronic Low Back Pain, Self-Management
Interventions: Problem-solving Pain to Enhance Living Well (PROPEL); Behavioral
Lead sponsor: University of Connecticut; Other
Eligibility: 18 Years to 60 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: Storrs, Connecticut

Conditions: Periimplantitis
Interventions: Gingival biopsy and blood sample collection; Procedure
Lead sponsor: NYU College of Dentistry; Other
Eligibility: 20 Years to 90 Years
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: New York, New York

Conditions: Down Syndrome, Alzheimer's Dementia
Interventions: biospecimen collection, cognitive assessments, caregiver questionnaire, Florbetapir F18 imaging, MRI, Fludeoxyglucose F18 (FDG), Tau Pet, Actigraphy; Procedure · Other
Lead sponsor: St. Joseph's Hospital and Medical Center, Phoenix; Other
Eligibility: 21 Years and older
Enrollment: 19 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Phoenix, Arizona

Conditions: Lung Non-Small Cell Carcinoma
Interventions: Chemotherapy, Immunotherapy, Intensity-Modulated Radiation Therapy, Computed Tomography, Magnetic Resonance Imaging, Fludeoxyglucose F-18, Biospecimen Collection; Drug · Other · Radiation + 1 more
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older
Enrollment: 164 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2036
U.S. locations: 125
States / cities: Jonesboro, Arkansas • Los Angeles, California • Parker, Colorado + 95 more

Conditions: Breast Cancer Risk
Interventions: Breast Cancer Risk Reduction Household Intervention; Behavioral
Lead sponsor: Columbia University; Other
Eligibility: 10 Years to 65 Years · Female only
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020
U.S. locations: 1
States / cities: New York, New York

Conditions: Sarcoma
Interventions: nivolumab, ipilimumab; Drug
Lead sponsor: University of Rochester; Other
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Multiple Sclerosis, Healthy
Interventions: Blood sampling (MS), Blood sampling (controls); Other
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years to 60 Years
Enrollment: 161 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Pseudomyxoma Peritonei, Appendiceal Neoplasm, Cancer, Appendiceal
Interventions: Bio-specimen collection, Questionnaire; Other
Lead sponsor: Mercy Medical Center; Other
Eligibility: 18 Years to 80 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2024
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Mechanistic Self-Dehumanization Condition, Control Condition
Interventions: The Ten Item Personality Inventory, Mechanistic Self-Dehumanization Condition, Debrief, Control Condition, Clinical Interview, Self-Report Measures, Blood Draw; Other · Diagnostic Test
Lead sponsor: Florida State University; Other
Eligibility: 18 Years to 40 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Tallahassee, Florida

Conditions: Osteoarthritis of the Knee
Interventions: Blood Draw, Joint Aspirate Harvest; Procedure
Lead sponsor: Scuderi, Gaetano J., M.D.; Other
Eligibility: 19 Years to 65 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2018
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Neuroendocrine Tumors
Interventions: 18F-MFBG (meta-fluoro benzylguanidine), Positron emission tomography (PET) imaging, Blood draws; Radiation · Device · Other
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 5 Years and older
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2025
U.S. locations: 1
States / cities: New York, New York

Conditions: COVID-19
Interventions: Bio-Self COVID-19 Antigen Home Test, Standard of Care COVID-19 Test, RT-PCR Test; Device · Diagnostic Test
Lead sponsor: BioTeke USA, LLC; Industry
Eligibility: 2 Years to 94 Years
Enrollment: 282 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 3
States / cities: Miami, Florida • Tallahassee, Florida • Elkridge, Maryland

Conditions: Microsatellite Instability, Colorectal Cancer Stage IV
Interventions: Specimen Collection, Serial Liquid Biopsy; Procedure
Lead sponsor: University of Southern California; Other
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 2
States / cities: Los Angeles, California • Newport Beach, California

Conditions: HIV Infections
Interventions: Not listed
Lead sponsor: American Gene Technologies International Inc.; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 2
States / cities: Washington D.C., District of Columbia • Baltimore, Maryland

Conditions: Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma, Platinum-Resistant Primary Peritoneal Carcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Fallopian Tube Carcinosarcoma, Recurrent Female Reproductive System Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Ovarian Carcinosarcoma, Recurrent Platinum-Resistant Fallopian Tube Carcinoma, Recurrent Platinum-Resistant Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma, Recurrent Primary Peritoneal Carcinosarcoma, Refractory Fallopian Tube Carcinoma, Refractory Female Reproductive System Carcinoma, Refractory Ovarian Carcinoma, Refractory Primary Peritoneal Carcinoma
Interventions: Autologous MUC1-activated T-cells, Bendamustine, Biospecimen Collection, Computed Tomography, Cyclophosphamide, Echocardiography, Leukapheresis, Magnetic Resonance Imaging, Multigated Acquisition Scan, Positron Emission Tomography; Biological · Drug · Procedure
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older · Female only
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Scottsdale, Arizona

Conditions: Recurrent Diffuse Large B-Cell Lymphoma, Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements, Recurrent Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Refractory High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements, Refractory Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma
Interventions: Axicabtagene Ciloleucel, Biospecimen Collection, Chemotherapy, Fecal Microbiota Transplantation, Leukapheresis, Placebo Administration; Biological · Procedure · Drug
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Duarte, California

Conditions: Malignant Digestive System Neoplasm
Interventions: Biospecimen Collection, Capecitabine, Diltiazem Hydrochloride, Electrocardiogram, Fluorouracil, Holter Monitoring, Isosorbide Mononitrate, Medical Device Usage and Evaluation, Placebo Administration, Questionnaire Administration; Procedure · Drug · Device + 1 more
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Glial Tumor of Brain, Diffuse Intrinsic Pontine Glioma, Glioma
Interventions: Gemcitabine, Tumor biopsy and blood draw; Drug · Procedure
Lead sponsor: University of Michigan Rogel Cancer Center; Other
Eligibility: 3 Years to 17 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Hypoxic-Ischemic Encephalopathy
Interventions: Database Entry/Biospecimen Collection; Other
Lead sponsor: University of Florida; Other
Eligibility: 1 Day to 3 Weeks
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2045
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Estrogen Receptor-Positive Breast Carcinoma, HER2-Negative Breast Carcinoma, HER2-Positive Breast Carcinoma, Triple-Negative Breast Carcinoma
Interventions: Biospecimen Collection, Electronic Health Record Review, Survey Administration; Procedure · Other
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 5
States / cities: Goodyear, Arizona • Duarte, California • Irvine, California + 2 more

Conditions: Brain Metastases, Adult
Interventions: Patritumab deruxtecan; Drug
Lead sponsor: Mustafa Khasraw, MBChB, MD, FRCP, FRACP; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Chronic Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive
Interventions: Biospecimen Collection, Drug Withdrawn, Quality-of-Life Assessment, Questionnaire Administration, Tyrosine Kinase Inhibitor; Procedure · Other · Drug
Lead sponsor: Children's Oncology Group; Network
Eligibility: Up to 25 Years
Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 157
States / cities: Birmingham, Alabama • Mobile, Alabama • Mesa, Arizona + 123 more

Conditions: Constitutional Mismatch Repair Deficiency Syndrome, Hematopoietic and Lymphoid Cell Neoplasm, Lynch Syndrome, Recurrent Lymphoma, Recurrent Malignant Solid Neoplasm, Recurrent Neuroblastoma, Recurrent Primary Central Nervous System Neoplasm, Refractory Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Neuroblastoma, Refractory Primary Central Nervous System Neoplasm, Xeroderma Pigmentosum
Interventions: Biospecimen Collection, Ipilimumab, Nivolumab; Procedure · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 12 Months to 25 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 7
States / cities: Palo Alto, California • Aurora, Colorado • St Louis, Missouri + 4 more

Conditions: Cancer
Interventions: Blood Samples; Other
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 4 Years to 100 Years
Enrollment: 198 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2018
U.S. locations: 1
States / cities: New York, New York

Search by objective public record fields.

Physical Activity on Neurophysiologic Gene Expression Profiles of Chronic Low Back Pain

The Role of Functional Epigenetic Modifications in Peri-Implantitis

Relationship Between Down Syndrome (DS) and Alzheimer's Disease (AD)

A Study of Targeted Post-Surgery Radiation Therapy for Non-Small Cell Lung Cancer With Remaining Lymph Node Cancer After Treatment

Family-Based Intervention Study of the Effects of Environmental Exposures on Breast Tissue Composition

Immunotherapy + Radiation in Resectable Soft Tissue Sarcoma

Immune Profiling During Ocrelizumab Treatment in Multiple Sclerosis

Gastrointestinal Microbiome Study of Appendiceal Cancer

Inducing Self-Dehumanization to Examine Oxytocin and Suicide Risk

Serum and Synovium Protease Inhibitor Levels in Primary and Secondary Osteoarthritic Joints

18F-MFBG Imaging for Evaluation of Neuroendocrine Malignancies

Clinical Performance Evaluation of the Bio-Self™ COVID-19 Antigen Home Test

Detection of MSI in Circulating Tumor DNA of Colorectal Carcinoma Patients

Developing a Functional Cure for HIV Disease: Clinical Specimen Collection From HIV Positive Individuals

MUC1-Activated T Cells for the Treatment of Relapsed and Resistant Ovarian Cancer

Fecal Microbiome Transplant to Remodel Intestinal Microbiota for Patients With Relapsed or Refractory Lymphoma With Exposure to High-Risk Antibiotics Who Are Receiving Chimeric Antigen Receptor T Cells

Vasodilator Therapy With Isosorbide Mononitrate or Diltiazem to Reduce Vasotoxicity in Patients With Gastrointestinal Cancer Receiving Fluoropyrimidine Therapy

Gemcitabine in Newly-Diagnosed Diffuse Midline Glioma

Florida Neonatal Neurologic Network

Circulating Tumor DNA Based Minimal Residual Disease Detection for Patients With Early-Stage Breast Cancer

A Window of Opportunity Study of Patritumab Deruxtecan in Patients With Brain Metastases

Stopping Tyrosine Kinase Inhibitors in Affecting Treatment-Free Remission in Patients With Chronic Phase Chronic Myeloid Leukemia

Testing the Combination of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) in Children, Adolescent, and Young Adult Patients With Relapsed/Refractory Cancers That Have an Increased Number of Genetic Changes, The 3CI Study

Radiation Biodosimetry in Patients Treated With Total Body Irradiation (TBI)